Skip to content

B-Complex: A Nutraceutical SANS Countermeasure

B-Complex: A Nutraceutical SANS Countermeasure

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05366933
Enrollment
16
Registered
2022-05-09
Start date
2022-08-01
Completion date
2032-09-30
Last updated
2025-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endothelial Dysfunction, Optic Disc Edema

Brief summary

In this project, the investigators propose to test effectiveness of a daily nutraceutical supplement containing bioactive B vitamins to mitigate optic disc edema in astronauts. The proposed countermeasure is intended to maximize functioning of the one-carbon metabolic pathway to provide enough substrate and cofactors to overcome any genetic differences that may impact the efficiency of enzyme function. By optimizing the pathway, this will 1) optimize endothelial function by increasing eNOS coupling and nitric oxide synthesis and 2) optimize collagen firmness and elasticity in the sclera and lamina cribrosa, and 3) minimize changes in total retinal thickness during and after flight. The protocol includes assessments of ocular health and function, along with determinants of vascular endothelial function, advanced glycation end products, and nutritional status and one carbon biochemistry. These additional measures will be critical for the further definition of the causes of optic disc edema in some astronauts after long-duration space flight, and in understanding the effect of the countermeasure. Finally, the supplemented subjects in this study will be compared against total retinal thickness data from previously flown astronauts known to have not taken supplements during their missions.

Detailed description

Fasting (8-h) blood samples (7.5 mL SST and 5 mL EDTA tubes, 12.5 mL total per session) will be collected approximately 180 days and 45 days before flight, on approximate flight day 90, and 30 days before landing, Return to Earth +0-2 days and 30 days after landing. Blood samples will be analyzed for vitamin status and one-carbon biochemistry, as previously described. One blood sample (collected before flight) will be analyzed for approximately 511 SNPs matching the profile of testing from our ongoing research related to optic disc edema. Serum samples will be analyzed for biochemistry measures evaluating endothelial function, vitamin status, and oxidative damage. Nutritional status assessment data, including inflight dietary intake and body mass data, completed for routine medical requirements will be requested for data sharing. Inflight medical exercise log data as well as available standard measures data will also be requested for data sharing. Medication use/Med Logs will also be requested for data sharing. Vascular function VENDYS-II (Endothelix, Inc) will be used to assess reactive hyperaemia through changes in fingertip temperature. The test consists of an automated blood pressure measurement followed by cuff occlusion of the right arm for 2 to 5 min. During this time, the fingertip temperature in the right hand decreases because of the lack of circulation in the fingertip. After the cuff is released, blood flow resumes, causing a temperature rebound in the fingertip in a manner that is proportional to vascular reactivity. Advanced Glycation End (AGE) Products Skin autofluorescence (SAF) will be analyzed non-invasively using an AGE reader (Diagnoptics Technologies, Groningen, the Netherlands). The AGE reader illuminates a skin surface of approximately 4 cm2, guarded against surrounding light, with an excitation light source with wavelength between 300 and 429 nm. This method is based on the fluorescent properties of certain AGEs accumulated in dermal tissue. OCT and OCT-A Optical coherence tomography (OCT) and OCT-angiography (OCT-A) scans will be acquired using the Spectralis OCT2 (Heidelberg Engineering) before, during, and after flight. The scan pattern includes 24 B-scans centered in a radial pattern over the optic nerve head, as well as a 3.5 mm circle scan surrounding the optic nerve head for assessment of retinal nerve fiber layer thickness and choroid thickness. For OCT-A, five consecutive volume scans will be obtained in these regions, each containing 216 A-scans. These images will be registered, and the consecutive B-scans will be used to calculate the decorrelation among the images to provide split-spectrum amplitude decorrelation angiography (SSADA) images. This decorrelation between consecutive B-scan images will be used to highlight locations where there is blood flow. The density of the perfused peripapillary vessels within the various layers of the retina will be calculated to create a flow density map.

Interventions

DRUGVitamin B-Complex Supplement

Vitamin B-Complex Supplement containing: 5-methyltetrahydrofolate, riboflavin 5 phosphate, pyridoxal phosphate, and methylcobalamin

Sponsors

Mayo Clinic
CollaboratorOTHER
Texas A&M University
CollaboratorOTHER
National Aeronautics and Space Administration (NASA)
Lead SponsorFED

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 100 Years
Healthy volunteers
Yes

Inclusion criteria

• Must be astronauts selected for 6-12 month missions on the International Space Station

Exclusion criteria

• Subjects taking B-vitamin supplements

Design outcomes

Primary

MeasureTime frameDescription
Optic Disc Edema6 monthsMeasure change in total retinal thickness during and after flight compared to preflight using OCT

Secondary

MeasureTime frameDescription
Advanced Glycation End Products (AGE)6 monthsSkin autofluorescence (SAF) will be analyzed non-invasively using an AGE reader
Serum folate status6 monthsVitamin status assessed from a fasting blood sample
Red Blood Cell folate status6 monthsVitamin status assessed from a fasting blood sample
Vitamin B6 status6 monthsVitamin status assessed from a fasting blood sample
Vitamin B12 status6 monthsVitamin status assessed from a fasting blood sample
Glucose6 monthsSerum glucose from a fasting blood sample
Nitric oxide6 monthsSerum nitric oxide from a fasting blood sample
tetrahydrobiopterin6 monthsSerum biochemistry from a fasting blood sample
Dihydrobiopterin6 monthsSerum biochemistry from a fasting blood sample
Oxidized glutathione6 monthsSerum biochemistry from a fasting blood sample
Total antioxidant capacity6 monthsSerum biochemistry from a fasting blood sample
Advanced glycation end products6 monthsSerum biochemistry from a fasting blood sample
Endothelial function6 monthsAssess reactive hyperemia through changes in fingertip temperature
Glycated albumin6 monthsSerum biochemistry from a fasting blood sample
3-nitrotyrosine6 monthsSerum biochemistry from a fasting blood sample
Formate6 monthsSerum biochemistry from a fasting blood sample
MMP-26 monthsSerum biochemistry from a fasting blood sample
MMP-96 monthsSerum biochemistry from a fasting blood sample
TIMP-16 monthsSerum biochemistry from a fasting blood sample
TIMP-26 monthsSerum biochemistry from a fasting blood sample
Heparan sulfate6 monthsSerum biochemistry from a fasting blood sample
Syndecan-16 monthsSerum biochemistry from a fasting blood sample
Glypican6 monthsSerum biochemistry from a fasting blood sample
Hyaluronan6 monthsSerum biochemistry from a fasting blood sample
Total lipid peroxides6 monthsSerum biochemistry from a fasting blood sample
Albumin6 monthsSerum biochemistry from a fasting blood sample

Countries

United States

Contacts

Primary ContactSara Zwart, PhD
sara.zwart-1@nasa.gov2814833753
Backup ContactEden Fields
eden.e.fields@nasa.gov2814837864

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026